Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2020 16:05 ET | Source: Prothena Corporation plc

Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease

First anti-alpha-synuclein antibody to advance into confirmatory large study in patients with early Parkinson’s disease; expected to initiate in 2021Prothena to earn a $60 million clinical milestone...
October 20, 2020 12:45 ET | Source: VALNEVA

Valneva annonce des résultats initiaux positifs pour la seconde Phase 2 du candidat vaccin contre la maladie de Lyme

Les critères d’évaluation de l’étude de Phase 2 VLA15-202 ont été atteints VLA15 a été généralement bien toléré pour toutes les doses et dans tous les groupes testésImmunogénicité renforcée dans...
October 20, 2020 12:45 ET | Source: VALNEVA

Valneva Announces Positive Initial Results for Second Phase 2 Study of Lyme Disease Vaccine Candidate VLA15

Phase 2 study VLA15-202 met its endpoints VLA15 generally safe across all dose and age groups tested Immunogenicity further increased in VLA15-202 compared to VLA15-201 Seroconversion Rates exceeded...
October 20, 2020 09:55 ET | Source: KuicK Research

Global Dendritic Cell Cancer Vaccine Immunotherapy Provenge Therapy Market & Clinical Trials Report 2026

DELHI, India, Oct. 20, 2020 (GLOBE NEWSWIRE) -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights: Global Dendritic...
October 20, 2020 08:30 ET | Source: Novavax, Inc.

Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020

GAITHERSBURG, Md., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
October 20, 2020 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)

First two participants dosed in a Phase 2 clinical trial of KER-050 in MDSInitial data expected by mid-2021 LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”...
October 20, 2020 08:00 ET | Source: CinCor Pharma, Inc.

CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects

CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that...
October 20, 2020 07:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs

LONDON and REDWOOD CITY, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused...
October 20, 2020 07:00 ET | Source: Newscope Capital Corporation

Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson's Disease

TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences...
October 20, 2020 06:00 ET | Source: CytoDyn Inc.

CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b/3 COVID-19 Registrational Trial

DSMC recommends CytoDyn continue the study as planned, with the protocol defined sample size and power to achieve the primary endpoint DSMC also requests another data review when enrollment reaches...